| Market Capitalization (Millions $) |
2,464 |
| Shares
Outstanding (Millions) |
189 |
| Employees |
13 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-32 |
| Cash Flow (TTM) (Millions $) |
82 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Sellas Life Sciences Group Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company's primary focus is on the development of galinpepimut-S (GPS), an investigational immunotherapy being evaluated for the treatment of multiple cancers, including acute myeloid leukemia and ovarian cancer.
Sellas Life Sciences aims to harness the power of the immune system to target and eliminate cancer cells. GPS stimulates the body's own immune system to recognize and attack cancer cells expressing specific target antigens. The company believes that this approach has the potential to provide safer and more effective treatment options for patients with various types of cancer.
Sellas Life Sciences has conducted numerous clinical trials to evaluate the safety and efficacy of GPS. The company has also entered into collaborations with other organizations to further explore the potential of their immunotherapies and expand their product pipeline.
Overall, Sellas Life Sciences Group Inc is dedicated to advancing innovative cancer immunotherapies with the goal of improving patient outcomes and addressing unmet medical needs in the field of oncology.
Company Address: 7 Times Square, Suite 2503, New York, 10036 NY
Company Phone Number: 200-5278 Stock Exchange / Ticker: NASDAQ SLS
|
1.88%